Disease Landscape and Forecast Insights

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…

The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by…

Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced…

The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and…

This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatment practices for…

China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved to treat this indication—Roche’s Herceptin as…

The highly genericized biguanides and sulfonylureas are, by far, the most heavily prescribed type 2 diabetes (T2D) drug classes. However, branded agents from several drug classes are jostling for…

While the incidence of gastric and GEJ adenocarcinoma continues to rise, efficacious treatment options, especially in the previously treated metastatic setting, remain limited. Cyramza (Eli Lilly)…

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s Keytruda…